Home > Healthcare > Drug Device Combination > Therapeutic Systems > Hydronephrosis Treatment Market

Hydronephrosis Treatment Market Share

Report ID: GMI8524
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Hydronephrosis Treatment Market Share

The hydronephrosis treatment industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy.

Hydronephrosis Treatment Market Companies

Some of the eminent market participants operating in the hydronephrosis treatment industry include:

AbbVie Inc
Amgen Inc
The Anthem Group
F. Hoffmann-La Roche Ltd
Nephrogenex Inc.
Novartis AG
Pfizer Inc.
Phraxis Inc.
Renal Associates P.A.
Sanofi

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global hydronephrosis treatment industry was valued at around USD 2.4 billion in 2023 and is expected to reach around USD 4.9 billion by 2032, driven by the growing prevalence of kidney diseases.

Intrinsic indication segment held leading revenue share in 2023 and is anticipated to reach USD 3.4 billion by 2032, driven by the growing incidence of conditions such as kidney stones, urinary tract infections (UTIs), benign prostatic hyperplasia (BPH), and pelvic tumors.

North America hydronephrosis treatment industry accounted for around USD 1 billion in 2023 and is predicted to witness substantial growth through 2032, driven by a well-developed healthcare infrastructure, with access to state-of-the-art medical technology and expertise.

AbbVie Inc, Amgen Inc, The Anthem Group, F. Hoffmann-La Roche Ltd, Nephrogenex Inc., Novartis AG, Pfizer Inc., Phraxis Inc., Renal Associates P.A., and Sanofi are some of the major industry contenders.